Training

Register now

Virtual meeting

Via Zoom

Description

This 1-hour training, intended for pharmacists and pharmacy technicians, will provide an overview of three pharmacological treatments that are available to patients with Opioid Use Disorders. The acitivity will dive into the differences between Agonists, Partial Agonists, and Antagonists for the treatment of Opioid Use Disorder. Additionally, the role of pharmacies for these three medication types will also be discussed.'

Participants are asked to complete the pre-test before the training and the post-test by 2/22/2022 in order to be issues continuing education credit. 

Intended audience

This activity is intended for pharmacists and pharmacy technicians working as part of the healthcare team to treat patients for substance use disorder.

Speakers

Jeffrey Bratberg

PharmD, FAPhA

University of Rhode Island Clinical Professor of Pharmacy Practice

Dr. Jeffrey Bratberg is well acquainted with the challenges community pharmacists and pharmacies face regarding opioid dispensing, safety, overdose and addiction. In 2012, Bratberg, along with a University of Rhode Island student pharmacist, co-developed an overdose education and naloxone training program for pharmacists in the first-in-nation statewide Collaborative Pharmacy Practice Agreement for naloxone. He is an unpaid consultant for prescribetoprevent.org, a website devoted to opioid overdose education and naloxone training, which hosts an online continuing professional education program that has trained over 10,000 pharmacists nationwide. In 2015, he was selected to serve as a member of the Rhode Island Governor’s Overdose Prevention and Intervention Task Force. He is a consultant or co-investigator on federal grants from the National Institute on Drug Abuse, Centers for Disease Control and Prevention, and Agency for Healthcare Research and Quality. Bratberg is the 2016 NASPA National Cardinal Health Generation Rx Award winner. The Generation Rx Champions Award honors a pharmacist who has demonstrated outstanding commitment to raising awareness of the dangers of Rx drug misuse among the general public, as well as the pharmacy community. Finally, Bratberg is the guest editor of the first ever special issue on Opioid Safety and Naloxone of the Journal of the American Pharmacists Association (Mar/April 2017).

Alyssa M. Peckham

PharmD, BCPP

Neuroscience Medical Science Liaison at Otsuka Pharmaceutical Companies

Dr. Alyssa Peckham is a board certified psychiatric clinical pharmacist specializing in various psychiatric and substance use disorders. She received her PharmD from the University of Rhode Island and completed two years of postgraduate residency training in psychiatry at the Veterans Affairs Hospital in Connecticut. Prior to her current role, she practiced as an advanced practice pharmacist in the Bridge Clinic at Massachusetts General Hospital in Boston which is a low threshold, harm reduction clinic for people with substance use disorders. Her research is focused on the use and misuse of prescriptions and other substances, with a focus on pharmacotherapy and harm reduction

Objectives

1. Classify the following for each of the three FDA-approved medication types (methadone, buprenorphine, and naltrexone) for opioid use disorder (OUD): pharmacology, use in OUD, place in therapy, safety, efficacy, and outcomes

2. Discuss treatment barriers, such as access and payment, for each of the three FDA-approved medication types for OUD and potential solution

3. Define the current role of the pharmacist in the treatment of OUD and potential role progression in the future

Sponsored by

Boston Medical Center Office-Based Addiction Treatment Training and Technical Assistance +, The Association for Multidisciplinary Education and Research in Substance Use and Addiction

Accreditation information

Hosted on: Zoom Webinar

Topic Designator: Drug Therapy

Activity Type: Knowledge-based

Pharmacist | UAN 0026-9999-22-099-L01-P

Pharmacy Technician | UAN 0026-9999-22-099-L01-T

Accreditation

Massachusetts College of Pharmacy and Health Sciences is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. MCPHS designates this educational activity for a total of 1.0 contact hours (0.10 CEUs).

Requirements for Credit

Attendance will be verified. Partial credit will not be awarded. Credit will not be issued to participants who join the meeting more than 15 minutes after the start of the meeting or to those who depart early. In order to receive credit you will need to complete the session evaluation within two weeks of attending the event.

Statement of Disclosure

Massachusetts College of Pharmacy and Health Sciences adheres to the ACPE Standards for Integrity and Independence in Continuing Education.  It is the policy of MCPHS that the speakers and planning committee members disclose all financial relationships with ineligible companies, and that relevant conflicts of interest are mitigated.  Speakers will disclose any unlabeled/unapproved use of drugs or devices during their presentation.

Alyssa M. Peckham holds no relevant financial relationship with ineligible companies.

Jeffery Bratberg holds no relevant financial relationship with ineligible companies.

OBAT TTA planning committee members have no relevant financial relationships with ineligible companies to disclose.

All MCPHS CE staff members have no relevant financial relationships with ineligible companies to disclose.

Register now